(Q38083077)

28 August 2017

title

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765). (English)

1 reference

28 August 2017

1 reference

ChEBI release 2020-05-28

Jan A Burger

1

1 reference

28 August 2017

Joseph J Buggy

series ordinal

2

1 reference

28 August 2017

publication date

28 August 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

54

1 reference

28 August 2017

issue

11

1 reference

28 August 2017

page(s)

2385-2391

1 reference

The B cell antigen receptor controls integrin activity through Btk and PLCgamma2.

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.777837

Roles for phosphoinositide 3-kinases, Bruton's tyrosine kinase, and Jun kinases in B lymphocyte chemotaxis and homing.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.777837

Expression of Bruton's tyrosine kinase protein within the B cell lineage

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.777837

Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.777837

The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.777837

Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.777837

Primary B cell immunodeficiencies: comparisons and contrasts

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.777837

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.777837

The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.777837

Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.777837

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.777837

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.777837

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.777837

B cell antigen receptor signaling: roles in cell development and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.777837

Mechanisms of B-cell lymphoma pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.777837

Nurture versus nature: the microenvironment in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.777837

B-cell receptor signaling in chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.777837

The B-cell receptor signaling pathway as a therapeutic target in CLL.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.777837

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.777837

Chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.777837

Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.777837

Chronic lymphocytic leukemia: a tale of one or two signals?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.777837

A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.777837

Stereotypical chronic lymphocytic leukemia B-cell receptors recognize survival promoting antigens on stromal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.777837

Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.777837

The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.777837

Antigen receptors on B lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.777837

Intrinsic properties of immunoglobulin IgG1 isotype-switched B cell receptors promote microclustering and the initiation of signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.777837

The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.777837

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.777837

The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.777837

Targeted covalent drugs of the kinase family

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.777837

Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.777837

The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.777837

B-cell receptor triggers drug sensitivity of primary CLL cells by controlling glucosylation of ceramides

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.777837

Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.777837

Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.777837

Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.777837

Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.777837

The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.777837

Augmented TLR9-induced Btk activation in PIR-B-deficient B-1 cells provokes excessive autoantibody production and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.777837

Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.777837

Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.777837

Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.777837

Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.777837

A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.777837

Antigen receptor stereotypy across B-cell lymphoproliferations: the case of IGHV4-59/IGKV3-20 receptors with rheumatoid factor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.777837

Bruton's Tyrosine Kinase and Phospholipase Cγ2 Mediate Chemokine-Controlled B Cell Migration and Homing

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.777837

10.3109/10428194.2013.777837

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference